Aclaris Therapeutics (ACRS) vs Bicara Therapeutics (BCAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 37.1% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $545.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | BCAX |
|---|---|---|
| Share price | $3.44 | $8.44 |
| Market cap | $545.63M | $560.31M |
| 1-day change | -1.71% | -7.46% |
| YTD return | +14.29% | -49.85% |
| 1-year return | +37.05% | -53.22% |
| 5-year return | -72.74% | — |
| EPS (TTM) | $-0.59 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.83M | — |
| Revenue growth (YoY) | -58.19% | — |
| Net income (latest FY) | $-64.92M | $-137.95M |
| Gross margin | 73.28% | — |
| Operating margin | -975.91% | — |
| Net margin | -829.58% | — |
| 52-week high | $6.60 | $30.99 |
| 52-week low | $2.46 | $7.87 |
| Distance from 52-week high | -47.88% | -72.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +205.23% | +281.16% |
| Average volume | 3.07M | 1.20M |
| Shares outstanding | 158.61M | 66.39M |
| Employees | 69 | 103 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed BCAX by 90.3 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
ACRS vs BCAX FAQ
Which is bigger, Aclaris Therapeutics or Bicara Therapeutics?
Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $545.63M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or BCAX?
ACRS returned +37.05% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Bicara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.